$STOK Q3 '26 Earnings Results & Recap
• Reported GAAP EPS of -$1.08 down -66.15% YoY
• Reported revenue of $11.26M up 5.93% YoY
• Stoke Therapeutics said its $358.8M in cash, cash equivalents and marketable securities as of September 30, 2026 is expected to fund operations into early 2028.